Skip to main content
Fig. 2 | Clinical Epigenetics

Fig. 2

From: Targeted demethylation of the SLC5A7 promotor inhibits colorectal cancer progression

Fig. 2

SLC5A7 methylation status and its correlation with SLC5A7 expression and prognosis of CRC patients. A DNA sequencing analysis showed that CpG island was enriched in 1800–2500 bp that can be potentially methylated. B Determination of SLC5A7 methylation in CRC tissues and paired normal colorectal tissues by time-of-flight mass spectrometry. The dots represent CpG sites and the color of the bar below from green to blue indicates β value range from 0 to 1. C SLC5A7 promotor methylation in 23 paired CRC tissues. D, E SLC5A7 methylation level analysis in tumor adjacent tissues and malignant tissues in HXCRC cohort (D) and TCGA-COAD cohort (E). F SLC5A7 mRNA expression in 23 paired CRC tissues. G SLC5A7 expression analysis in tumor adjacent tissues and malignant tissues in HXCRC cohort. H, I Correlation analysis between SLC5A7 methylation level and mRNA expression in HXCRC cohort (Pearson correlation, r = − 0.53, p < 0.001, H) and TCGA-COAD cohort (r = − 0.53, p < 0.001, I). J, K Kaplan–Meier analysis showing the disease-free survival of colon cancer patients in HXCRC cohort stratified by median SLC5A7 methylation level (n = 93; p = 0.0077; long-rank test, J), and overall survival (n = 93; p = 0.0067; long-rank test, K). L, M Kaplan–Meier analysis showing the disease-free survival of colon cancer patients in TCGA-COAD cohort stratified by median SLC5A7 methylation level (n = 318; p = 0.0115; long-rank test, L), and overall survival (n = 318; p = 0.0096; long-rank test, M)

Back to article page